All In Biotech

NDA 215401 · Noven Pharms INC

Xelstrym

Dextroamphetamine · Transdermal · Central Nervous System Stimulant

Last checked: Nov 19, 2026Latest source record: Jul 10, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Mar 22, 2022

Approved uses

1

Original approval plus efficacy supplements

Registered trials

183

36 Phase 3, 11 recruiting

FAERS reports

3,815

1,880 serious, 119 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: ABUSE, MISUSE, AND ADDICTION XELSTRYM has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including XELSTRYM, can result in overdose and death [see OVERDOSAGE (10) ] , and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. Before prescribing XELSTRYM, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout XELSTRYM treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction [see WARNINGS AND PRECAUTIONS (5.1) and DRUG ABUSE AND DEPENDENCE (9.2) ] . WARNING: ABUSE, MISUSE, AND...

What it is approved for

From the label in effect Oct 27, 2026.

XELSTRYM ® is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older [see CLINICAL STUDIES (14) ] . Limitations of Use The use of XELSTRYM is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage [see Warnings and Precautions (5.5) , Use in Specific Populations (8.4) ]. XELSTRYM is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older ( 1 ) Limitations of Use: The use of XELSTRYM is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage ( 5.5 , 8.4 ).

Mechanism: Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. The exact mode of therapeutic action in ADHD is not known.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • XELSTRYM · DEXTROAMPHETAMINE 18MG/9HR · SYSTEM, TRANSDERMAL · Prescription
  • XELSTRYM · DEXTROAMPHETAMINE 9MG/9HR · SYSTEM, TRANSDERMAL · Prescription
  • XELSTRYM · DEXTROAMPHETAMINE 13.5MG/9HR · SYSTEM, TRANSDERMAL · Prescription
  • XELSTRYM · DEXTROAMPHETAMINE 4.5MG/9HR · SYSTEM, TRANSDERMAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Dextroamphetamine" as an intervention, any sponsor and status, largest first.

All 183 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective386
  • fatigue305
  • nausea248
  • anxiety235
  • headache212
  • depression204
  • off label use186
  • insomnia149
  • pain149
  • condition aggravated143
  • dizziness143
  • somnolence143

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200522
200612
20075
200818
200924
201039
201153
201287
201357
201459
2015219
2016576
2017160
2018190
2019172
2020158
2021176
2022331
2023359
2024455
2025353
2026290

Recalls

1 FDA enforcement reports for this application.

  • Oct 31, 2024 · Class II · Ongoing

    Defective Delivery System: The product does not meet predetermined specifications for Coldflow (adhesive).

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Xelstrym (Dextroamphetamine)

2024 spending

$200K

Beneficiaries

131

417 claims

Per beneficiary

$1,526

$15.86 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$51,043
2024$199,942

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 245 on PubMed

Sponsor: Noven Pharms INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.